Core Insights - NeurAxis, Inc. has announced medical policy coverage for its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, IB-Stim, with a major insurer covering approximately 5.1 million members across 13 states [1] - The IB-Stim device is FDA-cleared for treating functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents aged 8-21 years [2] - The company has significantly expanded its insurance coverage from 4 million lives to 51 million lives in the past year, indicating strong growth and acceptance of its technology [3] Company Overview - NeurAxis, Inc. focuses on neuromodulation therapies for chronic and debilitating conditions in both children and adults, with a commitment to advancing science and evidence-based medicine [4] - The IB-Stim technology is currently the only FDA-cleared non-surgical option for children suffering from abdominal pain-related disorders of gut-brain interaction, addressing a significant unmet medical need [2][4] - Ongoing clinical trials are exploring the use of PENFS in various pediatric and adult conditions, further expanding the potential applications of the technology [4]
UPDATE - NeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States